Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell crawled time : 14:30 save search
Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care
Published: 2023-11-06 (Crawled : 14:30) - biospace.com/
ARE A | $116.51 0.05% -0.01% 1.1M
|
Finance
|
| O: -0.31%
H: 0.32%
C: -0.74%
GLPG | News | $28.9 -1.1% -1.11% 140K
|
Health Technology
|
| O: 4.99%
H: 0.15%
C: -2.11%
multi-year cell car-t agreement therapy
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform
Published: 2023-11-06 (Crawled : 14:30) - biospace.com/
CABA | $13.96 -7.86% -8.52% 1.1M
|
Health Technology
|
| O: 0.06%
H: 1.62%
C: -4.31%
caba-201 cell therapy platform
Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases
Published: 2023-09-07 (Crawled : 14:30) - biospace.com/
COYA | $8.53 3.52% 3.4% 30K
|
|
| O: 0.93%
H: 19.86%
C: 11.09%
cell protein therapeutics potential
Coya Therapeutics Announces Publication of Potential Novel Blood Biomarker Data in Amyotrophic Lateral Sclerosis (ALS) Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell (Treg) Enhancing Therapies
Published: 2023-08-31 (Crawled : 14:30) - biospace.com/
COYA | $8.53 3.52% 3.4% 30K
|
|
| O: -0.85%
H: 3.45%
C: 1.44%
biomarker publication sclerosis cell blood therapeutics potential
LAVA Therapeutics Presents Preclinical Data on its Gammabody™ T Cell Engager Platform at the 21st Annual PepTalk Conference
Published: 2022-01-18 (Crawled : 14:30) - biospace.com/
LVTX | $2.85 -3.06% -3.16% 100K
|
|
| O: 0.2%
H: 7.46%
C: 1.4%
conference therapeutics cel preclinical platform t-cell pre-clinical
ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing
Published: 2021-12-20 (Crawled : 14:30) - biospace.com/
IBRX | $4.92 -6.11% -6.5% 3.5M
|
Manufacturing
|
| O: 1.53%
H: 1.2%
C: -2.41%
AMRS | $0.05 -21.88% -16.36% 47M
|
Process Industries
|
| O: -2.79%
H: 1.93%
C: -3.72%
als bladder cancer trials trial covid cel clinical trials cancer vaccine phase 3 merge t-cell bladder
Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma
Published: 2021-12-06 (Crawled : 14:30) - prnewswire.com
CTXR | $0.8 -1.99% -2.02% 6.3M
|
Health Technology
|
| O: 2.65%
H: 0.0%
C: 0.0%
treatment immunotherapy therapy cancer phase 3 t-cell enroll ontak
Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy
Published: 2021-12-06 (Crawled : 14:30) - biospace.com/
ACET | $2.02 -11.01% -12.38% 930K
|
Health Technology
|
| O: 39.29%
H: 0.0%
C: 0.0%
positive therapy
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 60.78% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 900K
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.